Evidence map›Paper›PMID 35281932›Full record

ArticleFrontiers in pharmacology2022

Dapagliflozin Reduces Apoptosis of Diabetic Retina and Human Retinal Microvascular Endothelial Cells Through ERK1/2/cPLA2/AA/ROS Pathway Independent of Hypoglycemic.

Yuxin Hu, Qian Xu, Hongxue Li, Ziyu Meng, Ming Hao, Xuefei Ma, Wenjian Lin, Hongyu Kuang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
19.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yuxin HuThe Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Qian XuThe Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Hongxue LiThe Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Ziyu MengThe Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Ming HaoThe Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Xuefei MaThe Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Wenjian LinThe Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Hongyu KuangThe Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Harbin Medical University · CNFirst Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Apoptosisarachidonic aciddapagliflozindiabetic retinopathymetabolomics

Identifiers

PMID35281932
PMCPMC8908030
OpenAlexW4214661334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.